Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey

Fig. 2

Yearly changes of LDL-C in Lomitapide (green) and LA (light blue) cohort during follow-up. As the maximum duration of follow-up in the Lomitapide cohort was about 9 years, we compared the two cohorts in the same interval of time. Data are reported as mean values ± 2 standard errors per each time-point. A. HoFH subjects treated with lomitapide achieved significantly greater mean yearly LDL-C percent reduction from baseline as compared with those on LA. Data are reported as mean percent reduction ± 2 standard errors per each time-point. B. HoFH subjects treated with lomitapide achieved significantly lower mean yearly LDL-C values as compared with those on LA. Padj, value is adjusted for genotype, ethnicity, gender, untreated LDL-C and age at baseline. BL, baseline; LDL-C, low density lipoprotein cholesterol; LA, lipoprotein apheresis

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172